<DOC>
	<DOC>NCT00920361</DOC>
	<brief_summary>To evaluate dosage and administration method, efficacy and safety of Puregon and the relationship between background factors of patients and dose and administration method. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.</brief_summary>
	<brief_title>Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Patients who underwent IVF Patients with tumors of ovary, breast, uterus, pituitary or hypothalamus Pregnant or possible pregnant women, or lactating women Patients with undiagnosed atypical vaginal bleeding Patients with a history of hypersensitivity to any of the ingredients of this product. Patients with ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>